Vistagen Therapeutics, Inc.

Vistagen Therapeutics, Inc. is a late clinical-stage therapeutics company focused on developing and potentially commercializing new medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company operates in the highly competitive neuroscience and biopharmaceutical industry, which is subject to rapid and significant technological change. The large size and expanding scope of the neuroscience markets, especially the high unmet need in large and growing global markets for anxiety and depression disorders, make them attractive therapeutic areas for biopharmaceutical businesses. The company's five clinical-stage intranasal pherine product candidates each have a novel neurocircuitry-focused proposed mechanism of action and at least one positive clinical study in their targeted patient population.

The company faces potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical, and biotechnology companies, academic institutions and governmental agencies, and public and private research institutions. Several of these entities have robust drug pipelines, readily available capital, and large and established research and development and commercial organizations. For social anxiety disorder, the company is aware of companies developing therapies including Vanda Pharmaceuticals, Tonix Pharmaceuticals, Sensorium Therapeutics, and Engrail Therapeutics, among others. For major depressive disorder, competitors include Axsome Therapeutics, Definium Therapeutics, Xenon Pharmaceuticals, Johnson & Johnson, Usona Institute, Neumora Therapeutics, Boehringer Ingelheim, Syndeio Biosciences, Suven Life Sciences, GH Research, Draig Therapeutics, HMNC Brain Health, and Sirtsei Pharmaceuticals. For vasomotor symptoms due to menopause, competitors include Astellas Pharma, Bayer, Gedeon Richter, Changchun, AbCellera, Noema Pharma, Tioga Pharma, and Hansoh BioMedical. The company believes fasedienol has the potential to be the first FDA-approved acute treatment of SAD in adults, and may provide significant advantages relative to the current suboptimal standard of care.

The company generates revenue through sublicense and other revenue, primarily from its license and collaboration agreement with AffaMed Therapeutics, Inc. The company has no approved products or revenues from product sales to date. The core business model involves developing and potentially commercializing new medicines for psychiatric and neurological disorders, leveraging a deep understanding of nose-to-brain neurocircuitry. The company retains third parties for certain accounting, legal, manufacturing, nonclinical development, clinical development, and regulatory affairs support, and has the potential to pursue multiple strategic development and commercialization partnerships across its pipeline to efficiently unlock potential incremental value of its product candidate portfolio.

The company's most advanced intranasal pherine product candidate is fasedienol, being investigated in a U.S. Phase 3 development program for the acute treatment of social anxiety disorder. Fasedienol has received fast track designation from the FDA. The PALISADE Program includes the PALISADE-1, PALISADE-2, PALISADE-3, and PALISADE-4 Phase 3 clinical trials and a small exploratory Phase 2 repeat dose study. PALISADE-1, completed in 2022, did not achieve its primary endpoint. PALISADE-2 achieved its primary efficacy endpoint in August 2023. PALISADE-3, the randomized portion of which was completed in December 2025, did not achieve its primary endpoint. Topline results from the randomized portion of PALISADE-4 are expected in the second quarter of calendar 2026. The company has completed the randomized portion of the Repeat Dose Study and expects topline results in the third quarter of calendar 2026. As of May 31, 2026, the fasedienol clinical development program exceeded ICH E1 minimum recommendations with over 1,500 subjects receiving at least a single exposure to fasedienol, over 300 subjects with at least 6-months of exposure, and over 100 subjects with at least 12 months of exposure.

Itruvone is being developed for treatment of major depressive disorder and has received fast track designation from the FDA. In a randomized, double-blind, placebo-controlled parallel design exploratory Phase 2A clinical trial conducted in Mexico, itruvone reduced depressive symptoms as soon as one week based on the 17-item Hamilton Depression Scale scores compared to placebo. The company has an open IND for itruvone in the U.S. and plans to pursue Phase 2 clinical development. Refisolone is being developed for the treatment of moderate to severe vasomotor symptoms due to menopause. In April 2026, the company received a "Study May Proceed" letter from the FDA under its U.S. IND application for refisolone. In a randomized, double-blind, placebo-controlled exploratory Phase 2A clinical study conducted in Mexico, refisolone produced a significant reduction in the daily number of hot flashes compared to placebo at the end of the first week of treatment. PH15 is being developed for improvement of psychomotor impairment due to mental fatigue. In a randomized, double-blind, placebo-controlled, crossover Phase 2A pilot study conducted in Mexico, PH15 demonstrated a statistically significant improvement in reaction time and the number of errors as compared to placebo and caffeine. PH284 is being developed for the treatment of cancer cachexia. In a double-blind, placebo-controlled exploratory Phase 2A study in Mexico, PH284 induced a cumulative effect on mean Subjective Feeling of Hunger scores, as compared to placebo. AV-101 is an oral prodrug candidate that targets the NMDAR, and the company does not anticipate further development and commercialization of AV-101 on its own.

In June 2020, the company entered into a license and collaboration agreement with AffaMed Therapeutics, Inc., granting an exclusive license to develop, manufacture and commercialize fasedienol for multiple anxiety-related disorders in Greater China, South Korea and Southeast Asia. The company received an upfront payment of $5.0 million ¹ in August 2020. On September 1, 2023, the company entered into an Exclusive Negotiation Agreement with Fuji Pharma Co., Ltd. to negotiate exclusively a potential exclusive license agreement to develop and commercialize refisolone in Japan. The company received from Fuji Pharma a payment of $1.5 million ² as consideration for the Exclusive Negotiation Period. On March 5, 2026, the Board of Directors approved a reduction of approximately 20% ³ in the company's workforce. In connection with the workforce reduction, costs incurred were not material to the consolidated financial statements for the fiscal year ended March 31, 2026. Following the workforce reduction, in April 2026 the Compensation Committee approved retention stock option awards to all remaining employees under the Amended and Restated 2019 Omnibus Equity Incentive Plan, subject to time-based vesting over a two-year period.

The company is a clinical-stage biopharmaceutical company with no approved products or revenues from product sales. Net losses totaled $69.7 million ⁴ and $51.4 million ⁵ for the years ended March 31, 2026 and 2025, respectively. As of March 31, 2026 and 2025, the company had cash, cash equivalents, and marketable securities of $45.4 million ⁶ and $80.5 million ⁷. As of June 15, 2026, the issuance date of the consolidated financial statements, there is uncertainty about whether the company's combined cash, cash equivalents, and marketable securities will be sufficient to fund operations beyond twelve months from the issuance date, and therefore the company concluded that substantial doubt existed about the company's ability to continue as a going concern.

The primary growth vector is the continued development of fasedienol for the acute treatment of social anxiety disorder through the PALISADE Program. The company believes PALISADE-4, if successful, together with the positive results from PALISADE-2 and confirmatory evidence from the overall fasedienol development program in SAD, including the Repeat Dose Study and OLE data, as well as confirmatory evidence the company plans to generate based on FDA feedback to support the clinical meaningfulness of the duration and magnitude of effect of fasedienol, may establish substantial evidence of the effectiveness of fasedienol in support of a potential NDA submission for the acute treatment of SAD. The company plans to seek further feedback from the FDA regarding a potential NDA submission as it moves closer toward potential completion of Phase 3 development of fasedienol. The company also plans to pursue Phase 2 clinical development of itruvone in the U.S. for the treatment of MDD, building on the positive results from the previous exploratory Phase 2A clinical trial. The open IND for refisolone enables the company to pursue further Phase 2 clinical development in the U.S. for the treatment of moderate to severe VMS due to menopause, building on the successful exploratory Phase 2A clinical study.

The company is currently evaluating the potential Phase 2 development path forward for PH15 and the manufacturing, nonclinical and Phase 1 clinical programs required to support submission of a U.S. IND to facilitate further potential Phase 2 development of PH15 in the U.S. The company is also currently evaluating the potential path forward for PH284, including an assessment of the manufacturing, nonclinical and Phase 1 clinical programs required to support a U.S. IND application for potential further Phase 2 clinical development in the U.S. for the treatment of cancer cachexia or other appetite-related disorders. For AV-101, the company is currently assessing whether there is a path forward for potential third-party collaborative manufacturing, late-stage clinical development and commercialization for one or more neurological disorders involving the NMDAR.

The company's margin and cost outlook is focused on disciplined cash management. On March 5, 2026, the Board of Directors approved a reduction of approximately 20% ⁸ in the company's workforce, implemented to provide disciplined cash management while prioritizing efficient execution of the ongoing clinical studies in the PALISADE Program for fasedienol. Costs incurred in connection with the workforce reduction were not material to the consolidated financial statements for the fiscal year ended March 31, 2026. The company continues to rely on its network of third-party service providers and consultants to supplement its internal capabilities following the workforce reduction.

The company does not currently own or operate, nor does it plan to own or operate, manufacturing facilities for the production of its drug substances and drug product for nonclinical, clinical or commercial use. Manufacturing of pherine drug substances and drug product is performed by CDMOs who must comply with current good manufacturing practice regulations governed by the FDA. The company does not currently have any supply agreements in place with any CDMOs for either long-term supply or redundant supply. If pherine drug products are approved for commercial distribution, the company intends to execute long-term commercial supply agreement(s) with its CDMOs. The company plans to mitigate potential commercial supply risks through inventory management and through exploring additional back-up manufacturers, both in the U.S. and outside the U.S. The company retains third parties for certain accounting, legal, manufacturing, nonclinical development, clinical development, and regulatory affairs support.

The company does not provide specific R&D spending levels, capital expenditure plans, share repurchase authorization amounts, or dividend policy figures in the filing. The company expects to continue to spend substantial amounts of cash to continue the preclinical and clinical development of its product candidates. As of March 31, 2026 and 2025, the company had cash, cash equivalents, and marketable securities of $45.4 million ⁹ and $80.5 million ¹⁰. As of June 15, 2026, there is uncertainty about whether the company's combined cash, cash equivalents, and marketable securities will be sufficient to fund operations beyond twelve months from the issuance date of the consolidated financial statements.

The company faces significant structural headwinds including the need for substantial additional financing to execute its long-term business plan. The company has incurred significant net losses since inception and expects to continue to incur substantial operating losses for the foreseeable future. The company depends heavily on the success of fasedienol and cannot be certain that ongoing clinical trials, including PALISADE-4, will produce successful results or that the company will be able to obtain regulatory approval for fasedienol or any of its current or future product candidates. The company operates in highly competitive and rapidly changing industries, which may result in others discovering, developing or commercializing competing products before or more successfully than the company does.

The company has identified several execution risks that management explicitly flagged to the growth plan. The company's ability to retain or attract key management and scientific personnel and effectively manage the impact of the recent workforce reduction is a risk. The company relies on third party collaborators to assist in conducting nonclinical studies and clinical trials, and if they do not perform satisfactorily, the company may not be able to obtain regulatory approval or commercialize its product candidates. Raising additional capital in equity-based financing transactions will cause substantial dilution to existing stockholders. The company is focused on novel neuroscience drug development, a field that has seen very limited success, and the ability to successfully develop product candidates in this field is extremely difficult and subject to a number of unique challenges.

The company requires substantial additional financing to execute its long-term business plan and to continue to operate as a going concern, as there is uncertainty about whether its combined cash, cash equivalents, and marketable securities of $45.4 million ¹¹ as of March 31, 2026 will be sufficient to fund operations beyond twelve months from the issuance date of the financial statements. The company depends heavily on the success of fasedienol, and failures of ongoing or future clinical trials, such as PALISADE-1 and PALISADE-3 which did not achieve their primary endpoints, could delay, prevent or limit the company's ability to generate revenue. The company has incurred significant net losses since inception, totaling $69.7 million ¹² and $51.4 million ¹³ for the years ended March 31, 2026 and 2025, respectively, and expects to continue to incur substantial operating losses for the foreseeable future. The company operates in highly competitive and rapidly changing industries, and competitors may have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products. The company's ability to retain or attract key management and scientific personnel and effectively manage the impact of the recent workforce reduction of approximately 20% ¹⁴ is a material risk to its operations.

The overall tone of management's message is focused on disciplined cash management while prioritizing efficient execution of ongoing clinical studies, particularly the PALISADE Program for fasedienol. Management emphasizes the potential of fasedienol to be the first FDA-approved acute treatment of SAD in adults, and the company's belief that PALISADE-4, if successful, together with positive results from PALISADE-2 and confirmatory evidence from the overall fasedienol development program, may establish substantial evidence of effectiveness in support of a potential NDA submission. The strategic priorities emphasized are: advancing the PALISADE Program for fasedienol, pursuing Phase 2 clinical development of itruvone and refisolone in the U.S., and evaluating the potential path forward for PH15, PH284, and AV-101. The company also emphasizes its potential to pursue multiple strategic development and commercialization partnerships across its pipeline to efficiently unlock potential incremental value.